A drug for severe frostbite to keep limbs viable
Part of Injuries & trauma clinical trials.
This trial tests a drug called epoprostenol, given with standard care, to see if it helps people with severe frostbite by improving blood flow and reducing tissue damage. It may help save fingers and toes from needing amputation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must be admitted to the University of Colorado Hospital Burn and Frostbite Center.
- Your frostbite must be serious (grade 2 to 4), but not so severe that amputation is already needed.
- You must start the treatment within 72 hours after your frostbitten area is rewarmed.
- You cannot have certain heart conditions, low blood pressure, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a medicine called iloprost, given through an IV line, can help treat severe frostbite at high altitudes. It may help save damaged tissue and improve recovery for people with severe frostbite.
This study tests whether adding a medicine called prostacyclin (which helps keep blood from clotting) to the standard blood thinner can help children on ECMO—a machine that takes over heart and lung function—have fewer clotting problems and bleeding issues.
This trial tests a medication called treprostinil to see if it can help people who have frequent Raynaud's attacks. It is for patients with primary or secondary Raynaud's (related to conditions like scleroderma or lupus) who still have attacks despite current treatments.
This early-phase study tests whether treprostinil (Remodulin®) can reduce injury to a transplanted kidney right after surgery. If it works and is safe, it may help improve outcomes for people receiving a deceased-donor kidney transplant.
This study tests a medicine called prostacyclin (given through a vein) to see if it helps people on a breathing machine with a lung infection. The goal is to reduce inflammation and improve recovery.
This study tests an inhaled medication called treprostinil to see if it can reduce the number and severity of Raynaud's attacks in people with scleroderma (systemic sclerosis). If you have frequent Raynaud's attacks, this treatment might help you.
Hear when a new Frostbite trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.